Heparin-induced thrombocytopenia: Natural history, diagnosis, and management

Vascular Medicine

Volumn 6, Issue 2, 2001, Pages 113-119

  Deitcher, S R ^a   Carman, T L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Argatroban; Danaparoid; Heparin; Lepirudin; Platelet; Thrombo sis; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; DANAPAROID; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; ILOPROST; IMMUNOGLOBULIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN DERIVATIVE; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; HUMAN; IMMUNOASSAY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 0034866893     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/135886301680223653     Document Type: Review

References (65)

1. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
2. Heparin-induced thrombocytopenia
3. Heparin-induced thrombocytopenia
4. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis
5. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
6. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
7. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
8. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation
9. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
10. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia
11. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia
12. Heparin-associated thrombocytopenia
13. Heparin-induced thrombocytopenia
14. Heparin-associated thrombocytopenia: A critical review and pooled analysis
15. A 14-year study of heparin-induced thrombocytopenia
16. Heparin-associated thrombocytopenia: A comparison of three heparin preparations
17. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin
18. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes
19. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery
20. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implication for heparin-induced thrombocytopenia
21. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery
22. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts
23. Pediatric heparin-induced thrombocytopenia: Management with danaparoid (Orgaran)
24. Heparin-associated thrombocytopenia and thrombosis
25. Heparin-induced thrombosis: An important complication of heparin prophylaxis for thromboembolic disease in surgery
26. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass
27. Heparin-induced skin lesions
28. Heparin-induced thrombocytopenia and recurrent thromboembolism
29. Acute systemic reactions to intravenous bolus heparin therapy: Characterization and relationship to heparin-induced thrombocytopenia
30. Heparin-related thrombosis despite normal platelet counts in vascular surgery
31. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction
32. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia
33. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia
34. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
35. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep venous thrombosis of the legs: A multicentre prospective dose-ranging randomized trial
36. The development of hirudin as an antithrombotic drug
37. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia
38. Heparin-induced thrombocytopenia: Towards consensus
39. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
40. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time
41. Refludan™ (lepirudan) in pediatrics: Safe use for heparin-induced thrombocytopenia (HIT) and extracorporeal membrane oxygenation (ECMO)
42. Hirudin elimination by hemofiltration: A comparative in vitro study of different membranes
43. Anti-hirudin antibodies in patients treated with recombinant hirudin for more than five days, a prospective study
44. Novastan® (brand of argatroban): A small-molecule, direct thrombin inhibitor
45. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study
46. Argatroban use in patients with heparin-induced thrombocytopenia during percutaneous coronary intervention
47. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
48. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia
49. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
50. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses
51. Heparin-associated thrombocytopenia: Successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins
52. Persistent heparin-induced thrombocytopenia despite therapy with low molecular weight heparin
53. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia
54. Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular weight heparin (CY216)
55. Warfarin treatment of deep vein thrombosis complicating heparin-induced thrombocytopenia (HIT) is a risk factor for initiation of venous limb gangrene: Report of nine patients implicating the interacting procoagulant effects of two anticoagulant agents
56. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia
57. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374)
58. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia
59. In vitro inhibition of heparin-induced platelet aggregation in plasma from patients with HIT by SR121566, a newly developed GP IIb/IIIa antagonist
60. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT
61. Plasmapheresis in the management of heparin-induced thrombocytopenia
62. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeated heparin use in patients with a history of HIT
63. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia